Search Within

Matthew David Hellmann

  1. "Elsevier Inc."
Formats
  1. Meeting Abstract (47)
  2. Journal Article (27)
  3. Review (1)
Groups
  1. Department of Medicine (75)
  2. Solid Tumor Oncology Division (75)
  3. Thoracic Oncology (75)
  4. Weinberg Fellows (22)
  5. GSK Faculty (21)
  6. Department of Pathology and Laboratory Medicine (18)

More Groups

People
  1. Mark Kris (18)
  2. Hira Rizvi (17)
  3. Jamie Chaft (17)
  4. Charles Rudin (13)
  5. Michael Offin (9)
  6. Naiyer Rizvi (9)

More People

Years
  1. 2023 (4)
  2. 2022 (4)
  3. 2021 (6)
  4. 2020 (6)
  5. 2019 (12)
  6. 2018 (15)

More Years

Publications
  1. Journal of Thoracic Oncology (58)
  2. European Journal of Cancer (7)
  3. International Journal of Radiation Oncology, Biology, Physics (3)
  4. Radiotherapy and Oncology (3)
  5. Advances in Immunology (1)
  6. Advances in Radiation Oncology (1)

More Publications

Publishers
  1. Elsevier Inc. (75)

Results (75)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Factors associated with disease progression after discontinuation of immunotherapy for immune-related toxicity in non-small cell lung cancer
    Meeting Abstract

    Pecci, F.; Thummalapalli, R.; Alden, S.; Ricciuti, B.; Alessi, J. V.; Elkrief, A.; Rizvi, H.; Wang, X.; Egger, J. V.; Vaz, V. R.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Microsatellite instability defines a subset of lung cancers with smoking exposure, high tumor mutational burden and MLH1 inactivation
    Meeting Abstract

    Yang, S. R.; Gedvilaite, E.; Ptashkin, R.; Chang, J.; Ziegler, J.; Mata, D.; Villafania, L. B.; Nafa, K.; Hechtman, J. F.; Benhamida, J.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Clinical benefit from immunotherapy in patients with SCLC is associated with tumor capacity for antigen presentation
    Journal Article

    Rudin, C. M.; Balli, D.; Lai, W. V.; Richards, A. L.; Nguyen, E.; Egger, J. V.; Choudhury, N. J.; Sen, T.; Chow, A.; Poirier, J. T.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Baseline radiomic signature to estimate overall survival in patients with NSCLC
    Journal Article

    Dercle, L.; Fronheiser, M.; Rizvi, N. A.; Hellmann, M. D.; Maier, S.; Hayes, W.; Yang, H.; Guo, P.; Fojo, T.; Schwartz, L. H.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • A definitive prognostication system for patients with thoracic malignancies diagnosed with Coronavirus disease 2019: An update from the TERAVOLT registry
    Journal Article

    Whisenant, J. G.; Baena, J.; Cortellini, A.; Huang, L. C.; Lo Russo, G.; Porcu, L.; Wong, S. K.; Bestvina, C. M.; Hellmann, M. D.; Roca, E.; more...
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save
  • Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma Is affected by KRAS mutation status
    Journal Article

    Ricciuti, B.; Arbour, K. C.; Lin, J. J.; Vajdi, A.; Vokes, N.; Hong, L.; Zhang, J.; Tolstorukov, M. Y.; Li, Y. Y.; Spurr, L. F.; more...
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save
  • First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 checkmate 227 part 1 trial
    Journal Article

    Paz-Ares, L. G.; Ramalingam, S. S.; Ciuleanu, T. E.; Lee, J. S.; Urban, L.; Caro, R. B.; Park, K.; Sakai, H.; Ohe, Y.; Nishio, M.; more...
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save
  • Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab
    Journal Article

    Thor, M.; Shepherd, A. F.; Preeshagul, I.; Offin, M.; Gelblum, D. Y.; Wu, A. J.; Apte, A.; Simone, C. B. 2nd; Hellmann, M. D.; Rimner, A.; more...
    Radiotherapy and Oncology (2022)

    Fulltext@MSK | Save
  • Phase 3 study of first-line pembrolizumab ± vibostolimab (anti-TIGIT) in patients with PD-L1‒positive metastatic NSCLC
    Meeting Abstract

    Hellmann, M. D.; Cho, B. C.; Juergens, R.; Cheng, Y.; De Castro, G. Jr; Erman, M.; Bauman, J. R.; Takahashi, T.; Schwarzenberger, P.; Zhang, P.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Beyond steroids: Immunosuppressants in steroid-refractory or resistant immune-related adverse events
    Journal Article

    Luo, J.; Beattie, J. A.; Fuentes, P.; Rizvi, H.; Egger, J. V.; Kern, J. A.; Leung, D. Y. M.; Lacouture, M. E.; Kris, M. G.; Gambarin, M.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save